NURIX THERAPEUTICS, INC. Operating Expenses
NURIX THERAPEUTICS, INC. (NRIX) reported Operating Expenses of $103.25 million for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. operating expenses for the quarter ending 2026-05-31 was $103.25M, a 11.77% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating expenses for the quarter ending 2026-02-28 was $98.75M, a 21.43% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating expenses for the quarter ending 2025-11-30 was $96.67M, a 24.03% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating expenses for the quarter ending 2025-08-31 was $99.28M, a 47.74% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating expenses for fiscal 2025 was $369.65M, a 38.15% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. operating expenses for fiscal 2024 was $267.58M, a 15.31% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. operating expenses for fiscal 2023 was $232.05M, a 4.29% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. operating expenses for fiscal 2022 was $222.49M, a 50.70% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-05-31 | $103.25M 10-Q · filed 2026-07-09 | $201.99M 10-Q · filed 2026-07-09 | $298.67M derived: sum of 3 quarters · filed 2026-07-09 | $397.94M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $98.75M 10-Q · filed 2026-04-08 | $195.42M derived: sum of 2 quarters · filed 2026-04-08 | $294.70M derived: sum of 3 quarters · filed 2026-04-08 | $387.08M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $96.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $195.95M derived: sum of 2 quarters · filed 2026-01-28 | $288.33M derived: sum of 3 quarters · filed 2026-07-09 | $369.65M 10-K · filed 2026-01-28 |
| 2025-08-31 | $99.28M 10-Q · filed 2025-10-09 | $191.66M derived: sum of 2 quarters · filed 2026-07-09 | $272.97M 10-Q · filed 2025-10-09 | $350.92M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $92.38M 10-Q · filed 2026-07-09 | $173.69M 10-Q · filed 2026-07-09 | $251.64M derived: sum of 3 quarters · filed 2026-07-09 | $318.83M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $81.32M 10-Q · filed 2026-04-08 | $159.26M derived: sum of 2 quarters · filed 2026-04-08 | $226.46M derived: sum of 3 quarters · filed 2026-04-08 | $287.09M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $77.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $145.14M derived: sum of 2 quarters · filed 2026-01-28 | $205.77M derived: sum of 3 quarters · filed 2026-01-28 | $267.58M 10-K · filed 2026-01-28 |
| 2024-08-31 | $67.20M 10-Q · filed 2025-10-09 | $127.83M derived: sum of 2 quarters · filed 2025-10-09 | $189.63M 10-Q · filed 2025-10-09 | $250.13M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $60.63M 10-Q · filed 2025-07-09 | $122.44M 10-Q · filed 2025-07-09 | $182.93M derived: sum of 3 quarters · filed 2026-01-28 | $241.41M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $61.80M 10-Q · filed 2025-04-08 | $122.30M derived: sum of 2 quarters · filed 2026-01-28 | $180.78M derived: sum of 3 quarters · filed 2026-01-28 | $238.22M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $60.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $118.97M derived: sum of 2 quarters · filed 2026-01-28 | $176.41M derived: sum of 3 quarters · filed 2026-01-28 | $232.05M 10-K · filed 2026-01-28 |
| 2023-08-31 | $58.48M 10-Q · filed 2024-10-11 | $115.92M derived: sum of 2 quarters · filed 2024-10-11 | $171.56M 10-Q · filed 2024-10-11 | $227.03M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $57.44M 10-Q · filed 2024-07-11 | $113.08M 10-Q · filed 2024-07-11 | $168.55M derived: sum of 3 quarters · filed 2025-01-28 | $226.06M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $55.64M 10-Q · filed 2024-04-10 | $111.11M derived: sum of 2 quarters · filed 2025-01-28 | $168.62M derived: sum of 3 quarters · filed 2025-01-28 | $225.77M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | $55.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $112.98M derived: sum of 2 quarters · filed 2025-01-28 | $170.13M derived: sum of 3 quarters · filed 2025-01-28 | $222.49M 10-K · filed 2025-01-28 |
| 2022-08-31 | $57.51M 10-Q · filed 2023-10-12 | $114.66M derived: sum of 2 quarters · filed 2023-10-12 | $167.02M 10-Q · filed 2023-10-12 | $212.37M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $57.15M 10-Q · filed 2023-07-13 | $109.51M 10-Q · filed 2023-07-13 | $154.86M derived: sum of 3 quarters · filed 2023-07-13 | $194.11M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $52.37M 10-Q · filed 2023-04-13 | $97.71M derived: sum of 2 quarters · filed 2023-04-13 | $136.96M derived: sum of 3 quarters · filed 2023-04-13 | $170.47M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $45.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $84.60M derived: sum of 2 quarters · filed 2023-02-09 | $118.10M derived: sum of 3 quarters · filed 2023-02-09 | $147.64M 10-K · filed 2023-02-09 |
| 2021-08-31 | $39.25M 10-Q · filed 2022-10-06 | $72.75M derived: sum of 2 quarters · filed 2022-10-06 | $102.29M 10-Q · filed 2022-10-06 | $128.98M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $33.51M 10-Q · filed 2022-07-07 | $63.04M 10-Q · filed 2022-07-07 | $89.73M derived: sum of 3 quarters · filed 2022-07-07 | $113.01M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $29.53M 10-Q · filed 2022-04-08 | $56.23M derived: sum of 2 quarters · filed 2022-04-08 | $79.51M derived: sum of 3 quarters · filed 2022-04-08 | $96.92M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $26.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $49.97M derived: sum of 2 quarters · filed 2022-01-28 | $67.39M derived: sum of 3 quarters · filed 2022-01-28 | $82.80M 10-K · filed 2022-01-28 |
| 2020-08-31 | $23.28M 10-Q · filed 2021-10-14 | $40.69M derived: sum of 2 quarters · filed 2021-10-14 | $56.11M 10-Q · filed 2021-10-14 | $71.53M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $17.41M 10-Q · filed 2021-07-13 | $32.83M 10-Q · filed 2021-07-13 | $48.26M derived: sum of 3 quarters · filed 2022-01-28 | $61.45M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-02-29 | $15.42M 10-Q · filed 2021-04-13 | $30.84M derived: sum of 2 quarters · filed 2022-01-28 | $44.03M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2019-11-30 | $15.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $28.62M derived: sum of 2 quarters · filed 2022-01-28 | $53.35M 10-K · filed 2022-01-28 | |
| 2019-08-31 | $13.19M 10-Q · filed 2020-10-14 | $37.92M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |